See the published version of this preprint at Reproductive Biology and Endocrinology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Yan Gong
Sichuan University
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background Oxidative stress (OS), defined as an imbalance between reactive oxygen species (ROS) and/or reactive nitrogen species (RNS) excessive production and antioxidant insufficient, has been suggested to be involved in the pathogenesis of poor ovarian response (POR). Growth hormone (GH) can function reduce OS in some types of cells. This study investigated whether GH can significantly improve OS and in vitro fertilization and embryo transfer (IVF-ET) outcomes in patients with POR.
Methods This study enrolled 105 and 58 patients with and without POR (controls), respectively, diagnosed according to the Bologna criteria, who underwent conventional IVF-ET. Patients with POR were randomly assigned to two groups: POR-GH group: pretreatment with GH 4IU/d on day 2 of the previous menstrual cycle before IVF till the trigger day; POR-C group: no pretreatment. The markers of OS in follicle fluid (FF),reactive oxygen species (ROS) levels in granulosa cells (GC), and IVF outcomes of the patients were compared between the three groups.
Result(s) The endometrial thickness on trigger day, number of cleaved embryos, higher quality embryos, the rates of implantation and clinical pregnancy were significantly increased in POR-GH group compared with POR-C group (P<0.05). Moreover, the FF malondialdehyde (MDA), total oxidant status (TOS), oxidative stress index (OSI) and ROS levels in GC were significantly higher,whereas superoxide dismutase (SOD) and total antioxidant capacity (TAC) were significantly lower in POR-C group compared with non-POR group (P<0.05). Furthermore, the FF TAC was significantly increased, whereas TOS, OSI and intracellular ROS levels were significantly reduced in POR-GH group compared with POR-C group (P<0.05).
Conclusion(s) Pretreatment with GH alleviated OS and improved oocyte quality and IVF outcomes in patients with POR.
Clinical Trial Registration: Chinese Clinical Trial Registry. ChiCTR1900021269. Registered 8 February 2019, http://www.chictr.org.cn/edit.aspx?pid=35837&htm=4.
Keywords
Poor ovarian response, in vitro fertilization, growth hormone, oxidative stress, reactive oxygen species
Figure 1
Figure 2
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Reproductive Biology and Endocrinology.
No community comments so far
Editorial decision: Accept
On 23 Aug, 2020
Editor assigned
On 16 Aug, 2020
Submission checks complete
On 15 Aug, 2020
Editor invited
On 15 Aug, 2020
No comments provided
Editorial decision: Accept but Needs Editing
On 12 Aug, 2020
Review #1 received
Received 03 Aug, 2020
Reviewer #1 agreed
On 29 Jul, 2020
Reviewers invited
Invitations sent on 26 Jul, 2020
Editor assigned
On 08 Jul, 2020
Submission checks complete
On 07 Jul, 2020
Editor invited
On 07 Jul, 2020
No comments provided
Editorial decision: Minor revision
On 21 Jun, 2020
Review #1 received
Received 19 Jun, 2020
Reviewer #1 agreed
On 15 Jun, 2020
Reviewers invited
Invitations sent on 14 Jun, 2020
Editor assigned
On 24 May, 2020
Submission checks complete
On 23 May, 2020
Editor invited
On 23 May, 2020
Version 1
Posted 17 Mar, 2020
No comments provided
Editorial decision: Major revision
On 03 May, 2020
Review #1 received
Received 21 Apr, 2020
Reviewer #1 agreed
On 16 Apr, 2020
Reviewers invited
Invitations sent on 06 Apr, 2020
Editor assigned
On 13 Mar, 2020
First submitted
On 12 Mar, 2020
Submission checks complete
On 12 Mar, 2020
Editor invited
On 12 Mar, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Endocrinology & Metabolism
Learn more about our company.
See the published version of this preprint at Reproductive Biology and Endocrinology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Yan Gong
Sichuan University
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Reproductive Biology and Endocrinology.
No community comments so far
Editorial decision: Accept
On 23 Aug, 2020
Editor assigned
On 16 Aug, 2020
Submission checks complete
On 15 Aug, 2020
Editor invited
On 15 Aug, 2020
No comments provided
Editorial decision: Accept but Needs Editing
On 12 Aug, 2020
Review #1 received
Received 03 Aug, 2020
Reviewer #1 agreed
On 29 Jul, 2020
Reviewers invited
Invitations sent on 26 Jul, 2020
Editor assigned
On 08 Jul, 2020
Submission checks complete
On 07 Jul, 2020
Editor invited
On 07 Jul, 2020
No comments provided
Editorial decision: Minor revision
On 21 Jun, 2020
Review #1 received
Received 19 Jun, 2020
Reviewer #1 agreed
On 15 Jun, 2020
Reviewers invited
Invitations sent on 14 Jun, 2020
Editor assigned
On 24 May, 2020
Submission checks complete
On 23 May, 2020
Editor invited
On 23 May, 2020
Version 1
Posted 17 Mar, 2020
No comments provided
Editorial decision: Major revision
On 03 May, 2020
Review #1 received
Received 21 Apr, 2020
Reviewer #1 agreed
On 16 Apr, 2020
Reviewers invited
Invitations sent on 06 Apr, 2020
Editor assigned
On 13 Mar, 2020
First submitted
On 12 Mar, 2020
Submission checks complete
On 12 Mar, 2020
Editor invited
On 12 Mar, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Endocrinology & Metabolism
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Reproductive Biology and Endocrinology.
Background Oxidative stress (OS), defined as an imbalance between reactive oxygen species (ROS) and/or reactive nitrogen species (RNS) excessive production and antioxidant insufficient, has been suggested to be involved in the pathogenesis of poor ovarian response (POR). Growth hormone (GH) can function reduce OS in some types of cells. This study investigated whether GH can significantly improve OS and in vitro fertilization and embryo transfer (IVF-ET) outcomes in patients with POR.
Methods This study enrolled 105 and 58 patients with and without POR (controls), respectively, diagnosed according to the Bologna criteria, who underwent conventional IVF-ET. Patients with POR were randomly assigned to two groups: POR-GH group: pretreatment with GH 4IU/d on day 2 of the previous menstrual cycle before IVF till the trigger day; POR-C group: no pretreatment. The markers of OS in follicle fluid (FF),reactive oxygen species (ROS) levels in granulosa cells (GC), and IVF outcomes of the patients were compared between the three groups.
Result(s) The endometrial thickness on trigger day, number of cleaved embryos, higher quality embryos, the rates of implantation and clinical pregnancy were significantly increased in POR-GH group compared with POR-C group (P<0.05). Moreover, the FF malondialdehyde (MDA), total oxidant status (TOS), oxidative stress index (OSI) and ROS levels in GC were significantly higher,whereas superoxide dismutase (SOD) and total antioxidant capacity (TAC) were significantly lower in POR-C group compared with non-POR group (P<0.05). Furthermore, the FF TAC was significantly increased, whereas TOS, OSI and intracellular ROS levels were significantly reduced in POR-GH group compared with POR-C group (P<0.05).
Conclusion(s) Pretreatment with GH alleviated OS and improved oocyte quality and IVF outcomes in patients with POR.
Clinical Trial Registration: Chinese Clinical Trial Registry. ChiCTR1900021269. Registered 8 February 2019, http://www.chictr.org.cn/edit.aspx?pid=35837&htm=4.
Figure 1
Figure 2
This is a list of supplementary files associated with this preprint. Click to download.
Loading...